葉黃素 Lutein × 老年性黃斑部病變
The evidence anchors on AREDS2 (NEI/NIH phase-3 RCT, n=4,203, 5-year, plus a 10-year follow-up Report 28), an unusually robust evidence base for a supplement claim.
The evidence anchors on AREDS2 (NEI/NIH phase-3 RCT, n=4,203, 5-year, plus a 10-year follow-up Report 28), an unusually robust evidence base for a supplement claim. Lutein/zeaxanthin significantly slowed progression to advanced AMD in the pre-specified lowest-dietary-intake subgroup (HR 0.74) and was significantly superior to beta-carotene in a direct comparison (HR 0.82 for late AMD, HR 0.78 for neovascular AMD), with the 10-year follow-up confirming benefit and the absence of lung-cancer risk. Authoritative bodies are consistent and supportive: AAO's Preferred Practice Pattern formally recommends the AREDS2 formula, NEI quantifies a ~25% risk reduction in low-intake individuals, and NIH ODS, Mayo, Cleveland Clinic and Harvard all endorse it for intermediate/advanced AMD. The grade is held at B rather than A because the AREDS2 primary intention-to-treat analysis did not reach significance overall (HR 0.90, P=.12), the significant benefit comes from subgroup and active-comparator analyses, lutein was delivered within a multi-component formula, and the 2017 Cochrane review rated standalone lutein/zeaxanthin evidence as low-certainty with limited effect. The Examine L1 not_found result is a coverage gap (Examine files most lutein-for-eye research under other entries) and does not weaken the underlying evidence.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.695
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群（PTT regimen/Health/WomenTalk、Dcard、Mobile01）對葉黃素護眼討論非常熱絡，但實測體感分歧：純葉黃素多被嫌「無感」，加花青素/蝦紅素等複方較多人說有改善。理性版友反覆強調葉黃素是「預防保養」非「治療」，眼睛痠澀多來自疲勞而非缺葉黃素。業配與品牌推薦文密度偏高，需謹慎判讀。
分歧——純葉黃素多數反映無感，含花青素/蝦紅素/魚油的複方則較多人說眼睛乾澀痠澀有改善；對『黃斑部病變』本身的逆轉幾乎無人聲稱有體感
依論壇被提及頻率，非銷售或品質排序。
- 三多 葉黃素（平價單方，每日約 10 元，CP 值派常推）
- 善存（老牌綜合，知名度高）
- 大研生醫 視易適（含山桑子/花青素複方）
- 明守對策（分日夜錠複方，Mobile01 評價高）
- 白蘭氏 金盞花葉黃素（含蝦紅素，連鎖通路常見）
- 悠活原力（FloraGLO 游離型葉黃素）
- 三得利 / 17 喚 / 沈博士焦點葉黃素（Dcard 評比常被點名）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 戒菸
- 地中海飲食
- 抗血管內皮生長因子（anti-VEGF）眼內注射
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-amd-INT-lutein-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "葉黃素能改善老年性黃斑部病變",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}